Bethesda, MD, United States of America

Guillaume Stewart-Jones

This inventor holds 19 USPTO granted patents and 26 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Viral Immunogens. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, Dartmouth College. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guillaume Stewart-Jones. Retrieved from https://idiyas.com/inventor/guillaume-stewart-jones

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 10.7

ph-index = 3

Forward Citations = 34(Granted Patents)


Location History:

  • Bethesda, MD (US) (2018 - 2023)
  • Cambridge, MA (US) (2023 - 2024)

Company Filing History:


Years Active: 2018-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Recombinant Proteins
Metapneumovirus F
HIV-1 Envelope
Prefusion Immunogens
RSV F Proteins
Mumps Virus
Measles Virus
Nipah Virus
Vaccine Development
PIV F Immunogens
Viral Proteins
Immunogenicity
19 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Inventor Guillaume Stewart-Jones

Introduction

Guillaume Stewart-Jones is a notable inventor based in Bethesda, MD, renowned for his significant contributions to the field of biomedical research. With an impressive portfolio of 15 patents, he has been instrumental in advancing methodologies aimed at combating viral infections, including those caused by metapneumovirus and HIV-1. His innovative work in this area showcases the intersection of science and medicine, greatly impacting therapeutic approaches.

Latest Patents

Two of Guillaume Stewart-Jones's latest patents exemplify his groundbreaking work. The first patent involves recombinant metapneumovirus F proteins that are stabilized in a prefusion conformation. This innovation discloses nucleic acid molecules and vectors encoding these proteins, as well as methods for their use and production. In various applications, these proteins can be utilized to provoke an immune response to metapneumovirus in patients, enabling new strategies for treating or preventing infections.

The second patent focuses on recombinant HIV-1 envelope proteins. In this patent, HIV-1 Env ectodomain trimers are described as stabilized in a prefusion mature closed conformation. Similar to his work with metapneumovirus, these proteins and nucleic acid molecules can also generate an immune response to HIV-1, providing potential avenues for treatment or prevention of the virus.

Career Highlights

Guillaume Stewart-Jones has collaborated with reputable organizations such as the United States of America, represented by the Secretary of the Department of Health and Human Services, and the Institute for Research in Biomedicine. His experience in these institutions has facilitated the advancement of his research and innovation in viral infection therapeutics.

Collaborations

Throughout his career, Guillaume has worked alongside distinguished colleagues, including Baoshan Zhang and Yongping Yang. These collaborations have fostered a dynamic environment for scientific exploration and have contributed significantly to the development of cutting-edge biomedical solutions.

Conclusion

Guillaume Stewart-Jones represents the forefront of innovation in the field of biomedical research through his prolific inventions and patents. His work not only enhances our understanding of viral infections but also paves the way for future therapeutic interventions. As an inventor dedicated to addressing public health challenges, his contributions continue to inspire further research and development in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…